{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:47:48Z","timestamp":1791294468786,"version":"4.1.0"},"reference-count":268,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.bcp.2012.11.014","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T22:54:26Z","timestamp":1353624866000},"page":"289-305","source":"Crossref","is-referenced-by-count":183,"title":["Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis\u2014but what lies beyond?"],"prefix":"10.1016","volume":"85","author":[{"given":"Kevin","family":"Mullane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2012.11.014_bib0005","series-title":"Deaths: final data for 2008. National Vital Statistics Reports","author":"Mini\u00f1o","year":"2011"},{"key":"10.1016\/j.bcp.2012.11.014_bib0010","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1532-5415.2012.04056.x","article-title":"Burden of Alzheimer's disease\u2013related mortality in the United States, 1999-2008","volume":"60","author":"Moschetti","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bcp.2012.11.014_bib0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fphys.2012.00320","article-title":"Alzheimer's disease models and functional genomics-how many needles are there in the haystack?","volume":"3","author":"G\u00f6tz","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/JMN:17:2:101","article-title":"Pathologic correlates of non demented aging, mild cognitive impairment, and early-stage Alzheimer's disease","volume":"17","author":"Morris","year":"2001","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0025","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1523\/JNEUROSCI.5794-10.2011","article-title":"Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults","volume":"31","author":"Braskie","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0040","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006171","article-title":"The neuropsychological profile of Alzheimer disease","volume":"2","author":"Weintraub","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0045","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bcp.2011.01.021","article-title":"Developing predictive CSF biomarkers\u2014a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine","volume":"81","author":"Flood","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0050","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bcp.2012.11.014_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.bcp.2012.11.014_bib0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0070","doi-asserted-by":"crossref","first-page":"77sr1","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Science Transl Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0075","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.2885","article-title":"Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is \u2018too big to fail\u2019","volume":"224","author":"Castellani","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0080","doi-asserted-by":"crossref","first-page":"e31039","DOI":"10.1371\/journal.pone.0031039","article-title":"Rare variants in APP PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families","volume":"7","author":"Cruchaga","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2012.11.014_bib0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.neuron.2012.06.026","article-title":"Tau promotes neurodegeneration via DRP1 mislocalization in vivo","volume":"75","author":"DuBoff","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2012.11.014_bib0090","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2012.11.014_bib0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0197-4580(00)00211-6","article-title":"Copernicus revisited: amyloid beta in Alzheimer's disease","volume":"22","author":"Joseph","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9440(10)63936-3","article-title":"Do neurons have a choice in death?","volume":"158","author":"Perry","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2005.02.008","article-title":"Tau phosphorylation in Alzheimer's disease: pathogen or protector?","volume":"11","author":"Lee","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0110","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/NEN.0b013e318177eaf4","article-title":"Alzheimer disease pathology as a host response","volume":"67","author":"Castellani","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00401-006-0071-y","article-title":"Neuropathology of Alzheimer's Disease: pathognomonic but not pathogenic","volume":"111","author":"Castellani","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0120","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-\u03b2-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0125","doi-asserted-by":"crossref","first-page":"a00638","DOI":"10.1101\/cshperspect.a006387","article-title":"Treatment strategies targeting amyloid \u03b2-protein","volume":"2","author":"Schenk","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0130","doi-asserted-by":"crossref","first-page":"a006437","DOI":"10.1101\/cshperspect.a006437","article-title":"Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets","volume":"1","author":"Lee","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.0b013e318204a397","article-title":"Genome-wide association study of CSF biomarkers A\u03b21-42, t-tau, and p-tau181p in the ADNI cohort","volume":"76","author":"Kim","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2012.11.014_bib0140","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1373\/clinchem.2005.051201","article-title":"Amino-truncated \u03b2-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment","volume":"51","author":"Vanderstichele","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.bcp.2012.11.014_bib0145","doi-asserted-by":"crossref","first-page":"a006221","DOI":"10.1101\/cshperspect.a006221","article-title":"Fluid biomarkers in Alzheimer disease","volume":"2","author":"Blennow","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0155","unstructured":"Pharmaceutical Research and Manufacturer's of America. Alzheimer's research: setbacks and stepping stones; 2012. http:\/\/phrma.org\/sites\/default\/files\/1864\/alzheimersetbacksreportfinal912.pdf."},{"key":"10.1016\/j.bcp.2012.11.014_bib0160","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.331.7512.321","article-title":"Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials","volume":"331","author":"Kaduszkiewicz","year":"2005","journal-title":"Br Med J"},{"key":"10.1016\/j.bcp.2012.11.014_bib0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0175","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database System Rev"},{"key":"10.1016\/j.bcp.2012.11.014_bib0180","doi-asserted-by":"crossref","first-page":"e000917","DOI":"10.1136\/bmjopen-2012-000917","article-title":"Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review","volume":"2","author":"Farrimond","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.bcp.2012.11.014_bib0185","doi-asserted-by":"crossref","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","article-title":"The genetics of Alzheimer disease","volume":"2","author":"Tanzi","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng1934","article-title":"Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database","volume":"39","author":"Bertram","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0195","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/mp.2008.141","article-title":"Examination of the current top candidate genes for AD in a genome-wide association study","volume":"15","author":"Feulner","year":"2010","journal-title":"Mol Psychiatry 2009"},{"key":"10.1016\/j.bcp.2012.11.014_bib0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-2011-110824","article-title":"The role of variation at A\u03b2PP, PSEN1 PSEN2, and MAPT in late onset Alzheimer's disease","volume":"28","author":"Gerrish","year":"2012","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11920-011-0184-4","article-title":"Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer's disease","volume":"13","author":"Sherva","year":"2011","journal-title":"Curr Psychiatr Rep"},{"key":"10.1016\/j.bcp.2012.11.014_bib0210","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/1471-2164-9-516","article-title":"Establishing an adjusted p-value threshold to control the family-wide type 1 error in genome wide association studies","volume":"9","author":"Duggal","year":"2008","journal-title":"BMC Genom"},{"key":"10.1016\/j.bcp.2012.11.014_bib0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nprot.2010.182","article-title":"Basic statistical analysis in genetic case-control studies","volume":"6","author":"Clarke","year":"2011","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bcp.2012.11.014_bib0220","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0225","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0230","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2012.11.014_bib0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","article-title":"Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1 CD33 and CD2AP are associated with Alzheimer's disease","volume":"43","author":"Hollingworth","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0240","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP CD33 and EPHA1 are associated with late-onset Alzheimer's disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0245","doi-asserted-by":"crossref","first-page":"e16616","DOI":"10.1371\/journal.pone.0016616","article-title":"Meta-Analysis for Genome-Wide Association Study Identifies Multiple Variants at the BIN1 Locus Associated with Late-Onset Alzheimer's Disease","volume":"6","author":"Hu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2012.11.014_bib0250","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nature09410","article-title":"Hundreds of variants clustered in genomic loci and biological pathways affect human height","volume":"467","author":"Lango","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.11.014_bib0255","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pgen.0030097","article-title":"Combined genome scans for body stature in 6,602 European twins: evidence for common Caucasian loci","volume":"3","author":"Perola","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0260","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/sj.mp.4001935","article-title":"Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease","volume":"12","author":"Laws","year":"2007","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.bcp.2012.11.014_bib0265","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jnnp-2011-301413","article-title":"An evaluation of the impact of MAPT SNCA and APOE on the burden of Alzheimer's and Lewy body pathology","volume":"83","author":"Wider","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bcp.2012.11.014_bib0270","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/alzrt137","article-title":"Pooled-DNA sequencing identifies novel causative variants in PSEN1 GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort","volume":"4","author":"Jin","year":"2012","journal-title":"Alzheimer's Res Therap"},{"key":"10.1016\/j.bcp.2012.11.014_bib0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrg1767","article-title":"Structural variation in the human genome","volume":"7","author":"Feuk","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0280","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1200395","article-title":"Phenotypic heterogeneity of genomic disorders and rare copy-number variants","volume":"367","author":"Girirajan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0285","doi-asserted-by":"crossref","unstructured":"Swaminathan S, Kim S, Shen L, Risacher SL, Foroud T, Pankratz N, et al. Genomic copy number analysis in Alzheimer's disease and mild cognitive impairment: an ADNI study. Int J Alz Dis 2011;2011:ID 729478.","DOI":"10.4061\/2011\/729478"},{"key":"10.1016\/j.bcp.2012.11.014_bib0290","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Nat Acad Sci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0295","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ana.21736","article-title":"Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches","volume":"65","author":"Mahley","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0300","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/mp.2011.52","article-title":"APOE and Alzheimer disease: a major gene with semi-dominant inheritance","volume":"16","author":"Genin","year":"2011","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.bcp.2012.11.014_bib0305","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0168-9525(00)89161-1","article-title":"Genetic susceptibility to Alzheimer disease","volume":"11","author":"Pericak-Vance","year":"1995","journal-title":"Trends Genet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a009290","article-title":"Head injury and the risk of Alzheimer's disease","volume":"146","author":"O\u2019Meara","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/alzrt43","article-title":"Vascular health, diabetes, APOE and dementia: the aging, demographics and memory study","volume":"2","author":"Llewellyn","year":"2010","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib0320","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1021\/jm3008618","article-title":"Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology","volume":"55","author":"Mahley","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2012.11.014_bib0325","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.drudis.2012.01.004","article-title":"Translational semantics and infrastructure: another search for the Emperor's clothes","volume":"17","author":"Mullane","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bcp.2012.11.014_bib0330","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.112.192104","article-title":"Mitochondrial function and dysfunction\u2014an update","volume":"342","author":"Davis","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib0335","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.2225","article-title":"The future of genetic research on neurodegeneration","volume":"16","author":"Van Broeckhoven","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0340","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/489046a","article-title":"ENCODE: the human encyclopaedia","volume":"489","author":"Maher","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.11.014_bib0345","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1101\/gr.146506.112","article-title":"What does our genome encode?","volume":"22","author":"Stamatoyannopoulos","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.bcp.2012.11.014_bib0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0355","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2460","article-title":"Resolving controversies on the path to Alzheimer's therapeutics","volume":"17","author":"Selkoe","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0360","doi-asserted-by":"crossref","first-page":"a006379","DOI":"10.1101\/cshperspect.a006379","article-title":"Proteolytic degradation of amyloid \u03b2-protein","volume":"2","author":"Saido","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0365","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.biopsych.2010.09.020","article-title":"What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?","volume":"68","author":"Cummings","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bcp.2012.11.014_bib0370","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1523\/JNEUROSCI.4701-07.2007","article-title":"A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference","volume":"27","author":"Young-Pearse","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0375","doi-asserted-by":"crossref","first-page":"a006288","DOI":"10.1101\/cshperspect.a006288","article-title":"Physiological functions of APP family proteins","volume":"4","author":"Muller","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0380","doi-asserted-by":"crossref","first-page":"e29892","DOI":"10.1371\/journal.pone.0029892","article-title":"Amyloid precursor protein is required for normal function of the rod and cone pathways in the mouse retina","volume":"7","author":"Ho","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2012.11.014_bib0385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00221-012-3039-2","article-title":"The physiological functions of the \u03b2-amyloid precursor protein APP","volume":"217","author":"M\u00fcller","year":"2012","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.bcp.2012.11.014_bib0390","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1021\/bi802361k","article-title":"Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems","volume":"48","author":"Baruch-Suchodolsky","year":"2009","journal-title":"Biochem"},{"key":"10.1016\/j.bcp.2012.11.014_bib0395","doi-asserted-by":"crossref","first-page":"e9505","DOI":"10.1371\/journal.pone.0009505","article-title":"The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide","volume":"3","author":"Soscia","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2012.11.014_bib0400","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.molmed.2007.06.004","article-title":"Amyloid beta as a regulator of lipid homeostasis","volume":"13","author":"Grimm","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0405","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1096\/fj.02-0285fje","article-title":"Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity","volume":"6","author":"Yao","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2012.11.014_bib0410","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/nn.2433","article-title":"Amyloid-\u03b2 as a positive endogenous regulator of release probability at hippocampal synapses","volume":"12","author":"Abramov","year":"2009","journal-title":"Nature Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0415","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-2012-129033","article-title":"Amyloid-\u03b2 peptide: Dr. Jekyll or Mr. Hyde?","author":"Puzzo","year":"2012","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib0420","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2012.11.014_bib0425","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b2 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2012.11.014_bib0430","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI200318162","article-title":"NSAIDs and enantiomers of flurbiprofen target \u03b3-secretase and lower A\u03b242 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2012.11.014_bib0435","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0440","unstructured":"Pollack A. Myriad genetics stops work on Alzheimer's drug. New York Times; 2008, July 1, 2008. http:\/\/www.nytimes.com\/2008\/07\/01\/business\/01gene.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib0445","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WAD.0b013e31815d1048","article-title":"Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals","volume":"21","author":"Galasko","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.bcp.2012.11.014_bib0450","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. A randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2012.11.014_bib0455","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in Alzheimer's Disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J Alz Disease"},{"key":"10.1016\/j.bcp.2012.11.014_bib0460","doi-asserted-by":"crossref","unstructured":"Sperling RA, Jack Jr CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011:3:111cm33.","DOI":"10.1126\/scitranslmed.3002609"},{"key":"10.1016\/j.bcp.2012.11.014_bib0465","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656560903044982","article-title":"Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease","volume":"10","author":"Henley","year":"2009","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.bcp.2012.11.014_bib0470","unstructured":"Lilly Press Release. Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials, August 7, 2010. http:\/\/newsroom.lilly.com\/releasedetail.cfm?ReleaseID=499794."},{"key":"10.1016\/j.bcp.2012.11.014_bib0475","unstructured":"Lowe D. Lilly's gamma secretase inhibitor for alzheimer's: worse than nothing. Corante. In the Pipeline, 2010, August 18th, 2010. http:\/\/pipeline.corante.com\/archives\/2010\/08\/18\/lillys_gamma_secretase_inhibitor_for_alzheimers_worse_than_nothing.php."},{"key":"10.1016\/j.bcp.2012.11.014_bib0480","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble A\u03b2 peptide with tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0485","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12603-009-0217-4","article-title":"Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study","volume":"13","author":"Saumier","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0490","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0495","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BJ20120653","article-title":"Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?","volume":"446","author":"Teich","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2012.11.014_bib0500","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0505","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2012.11.014_bib0510","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2010.493872","article-title":"Bapineuzumab","volume":"10","author":"Kerchner","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib0515","unstructured":"Pfizer Press Release. Pfizer annunces topline results of first of four studies in bapineuzumab phase 3 program. July 23, 2012. http:\/\/www.businesswire.com\/news\/home\/20120723006412\/en\/Pfizer-Announces-Topline-Results-Studies-Bapineuzumab-Phase."},{"key":"10.1016\/j.bcp.2012.11.014_bib0520","unstructured":"Silverman, E. Bapi is a bust: Pfizer & J&JAlzheimer Med fails. PharmaBlog, August 7th, 2012. http:\/\/www.pharmalot.com\/2012\/08\/bapi-is-a-bust-pfizer-jj-alzheimer-med-fails\/."},{"key":"10.1016\/j.bcp.2012.11.014_bib0525","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0530","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlo","year":"2012","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.bcp.2012.11.014_bib0535","unstructured":"FierceBiotech. Eli Lilly and company announces top-line results on solanezumab phase 3 clinical trials in patients with Alzheimer's disease. August 24, 2012. http:\/\/www.fiercebiotech.com\/press-releases\/eli-lilly-and-company-announces-top-line-results-solanezumab-phase-3-clinic#ixzz25ehJqQTg."},{"key":"10.1016\/j.bcp.2012.11.014_bib0540","unstructured":"Lilly Press Release. Lilly announces detailed results of the Phase 3 Solanezumab EXPEDITION studies following a presentation of the independent analyses by the Alzheimer's Disease Cooperative Study (ADCS). October 8, 2012 http:\/\/www.prnewswire.com\/news-releases\/lilly-announces-detailed-results-of-the-phase-3-solanezumab-expedition-studies-following-a-presentation-of-the-independent-analyses-by-the-alzheimers-disease-cooperative-study-adcs-173144711.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib0545","unstructured":"Marchione M. Solanezumab, Alzheimer's Drug, shows some promise in mild disease. Huffington Post, October 8, 2012. http:\/\/www.huffingtonpost.com\/2012\/10\/08\/solanezumab-alzheimersdrug_n_1948969.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib0550","unstructured":"Rocoff JD. New data released on Lilly Alzheimer's drug. Wall St. J. 2012, October 8, 2012. http:\/\/online.wsj.com\/article\/SB10000872396390444897304578044520966644406.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib0555","unstructured":"Pierson R, Lilly trials boost amyloid link to Alzheimer's-analysis Chicago Tribune Health, October 29, 2012. http:\/\/www.chicagotribune.com\/health\/sns-rt-us-lilly-alzheimers-biomarkersbre89s15i-20121029,0,5485381.story."},{"key":"10.1016\/j.bcp.2012.11.014_bib0560","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1016\/j.jalz.2010.05.1015","article-title":"IP\/MS analysis of human CSF A\u03b2 following a single dose of the C-terminal anti-A\u03b2 antibody ponezumab (PF-04360365) to Alzheimer patients","volume":"6","author":"Wood","year":"2010","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.bcp.2012.11.014_bib0565","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/hv.7.3.14266","article-title":"Emerging antibody products and Nicotiana manufacturing","volume":"7","author":"Whaly","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.bcp.2012.11.014_bib0570","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2012.02.022","article-title":"Engineered antibody approaches for Alzheimer's disease immunotherapy","volume":"526","author":"Robert","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bcp.2012.11.014_bib0575","unstructured":"Hirschler B. Roche ramps up Alzheimer's drug trial as rivals stumble. Reuters, September 7, 2012. http:\/\/www.reuters.com\/article\/2012\/09\/07\/us-alzheimers-roche-trial-idUSBRE8860JO20120907."},{"key":"10.1016\/j.bcp.2012.11.014_bib0580","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrd3842","article-title":"Sting of Alzheimer's failures offset by upcoming prevention trials","volume":"11","author":"Mullard","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib0585","first-page":"426","article-title":"US government sets out Alzheimer's plan","volume":"485","author":"Wadman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0590","unstructured":"Purdy MC. Investigational drugs chosen for major Alzheimer's prevention trial. October 10, 2012. http:\/\/news.wustl.edu\/news\/Pages\/24400.aspx."},{"key":"10.1016\/j.bcp.2012.11.014_bib0595","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"A novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib0600","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0605","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique A\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0610","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.neurobiolaging.2012.01.047","article-title":"The safety and effectiveness of immune globulin intravenous (human), for the treatment of mild to moderate Alzheimer's disease","volume":"33","author":"Gelmont","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0615","unstructured":"Pollack A. Small trial hints drug can slow Alzheimer's. New York Times, July 17, 2012. http:\/\/www.nytimes.com\/2012\/07\/18\/business\/study-shows-drug-may-help-alzheimers-patients.html?_r=1."},{"key":"10.1016\/j.bcp.2012.11.014_bib0620","doi-asserted-by":"crossref","unstructured":"Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-\u03b2 production in vivo. Sci Transl Med 2011;3:84ra43.","DOI":"10.1126\/scitranslmed.3002254"},{"key":"10.1016\/j.bcp.2012.11.014_bib0625","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0630","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/emmm.201101084","article-title":"\u03b2-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment","volume":"4","author":"Cai","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0635","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.11.014_bib0640","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2011-111472","article-title":"Characterization of insulin degrading enzyme and other amyloid-\u03b2 degrading proteases in human serum: a role in Alzheimer's disease?","volume":"29","author":"Liu","year":"2012","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib0645","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1326-7-46","article-title":"Identification of BACE2 as an avid \u03b2-amyloid degrading protease","volume":"7","author":"Abdul-Hay","year":"2012","journal-title":"Mol Neurodeg"},{"key":"10.1016\/j.bcp.2012.11.014_bib0650","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the developemnt of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib0655","unstructured":"Sadeghi-Nejad N. The lessons of failure: what we can learn from bapineuzumab's blowup. Forbes August 7, 2012. http:\/\/www.forbes.com\/sites\/natesadeghi\/2012\/08\/07\/the-lessons-of-failure-what-we-can-learn-from-bapineuzumabs-blowup\/print\/."},{"key":"10.1016\/j.bcp.2012.11.014_bib0660","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMe1207995","article-title":"Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease","volume":"367","author":"Gandy","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0665","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/jpet.112.192120","article-title":"Oxidative shielding or oxidative stress","volume":"342","author":"Naviaux","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib0670","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S1474-4422(12)70256-9","article-title":"When, where, and how does Alzheimer's disease start?","volume":"11","author":"Fox","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0675","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1571-5078(07)07021-3","article-title":"Amyloidosis","volume":"7","author":"Gilmore","year":"2008","journal-title":"Handbook Syst Autoimm Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib0680","first-page":"797","article-title":"Amyloidosis. Also a heart disease","volume":"64","author":"Garcia-Pavia","year":"2011","journal-title":"Rev Resp Cardiol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0685","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cercor\/1.1.103","article-title":"The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease","volume":"1","author":"Arnold","year":"1991","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.bcp.2012.11.014_bib0690","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neurobiolaging.2003.09.009","article-title":"Spatial and temporal relationships between plaques and tangles in Alzheimer pathology","volume":"25","author":"Schoenheit","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0695","doi-asserted-by":"crossref","unstructured":"Ioannidis JPA. Extrapolating from animals to humans. Sci Transl Med 2012;4:151ps15.","DOI":"10.1126\/scitranslmed.3004631"},{"key":"10.1016\/j.bcp.2012.11.014_bib0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)57001-3","article-title":"Defining the role of pharmacology in the complex world of translational research","volume":"57","author":"Enna","year":"2009","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0705","first-page":"93","article-title":"Development, optimization and use of preclinical behavioral models to maximize the productivity of drug discovery in Alzheimer's disease","volume":"vol. 2","author":"Lindner","year":"2012"},{"key":"10.1016\/j.bcp.2012.11.014_bib0710","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17460441.2012.666234","article-title":"The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update","volume":"7","author":"Bales","year":"2012","journal-title":"Exp Opin Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib0715","doi-asserted-by":"crossref","first-page":"a006320","DOI":"10.1101\/cshperspect.a006320","article-title":"Animal models of Alzheimer disease","volume":"2","author":"LaFerla","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0720","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1001\/jama.2009.1863","article-title":"Late-life dementias. Does this unyielding global challenge 2012 require a broader view?","volume":"302","author":"Montine","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2012.11.014_bib0725","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0730","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMcibr1204890","article-title":"Preclinical success against Alzheimer's disease with an old drug","volume":"367","author":"La Furla","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0735","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMp1203104","article-title":"The ethics of early evidence\u2013preparing for a possible breakthrough in Alzheimer's Disease","volume":"367","author":"Lowenthal","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0740","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.326_386","article-title":"Alzheimer's biomarker initiative hits its stride","volume":"326","author":"Miller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0745","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3233\/JAD-2010-091504","article-title":"Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging","volume":"20","author":"Mosconi","year":"2010","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib0750","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1586\/ern.10.136","article-title":"Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease","volume":"10","author":"Herholz","year":"2010","journal-title":"Exp Rev Neurotherapeutics"},{"key":"10.1016\/j.bcp.2012.11.014_bib0755","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer's disease: academic, industry, and regulatory perspectives","volume":"7","author":"Hampel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib0760","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awq277","article-title":"Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease","volume":"133","author":"Jack","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2012.11.014_bib0765","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0770","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awl063","article-title":"CSF amyloid-\u03b2-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia","volume":"129","author":"Bibl","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2012.11.014_bib0775","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.20508","article-title":"Amyloid \u03b2 38, 40, and 42 species in cerebrospinal fluid: more of the same?","volume":"58","author":"Schoonenboom","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0780","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2012.11.014_bib0785","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/alzrt56","article-title":"Use of theragnostic markers to select drugs for phase II\/III trials for Alzheimer disease","volume":"2","author":"Zetterberg","year":"2010","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib0790","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0795","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1155\/2009\/609839","article-title":"Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo","volume":"21","author":"Rabinovici","year":"2009","journal-title":"Behav Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0800","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00401-009-0486-3","article-title":"Mechanisms of tau-induced neurodegeneration","volume":"118","author":"Iqbal","year":"2010","journal-title":"Acta Neuopathol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0805","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/bj3230577","article-title":"Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration","volume":"323","author":"Billingsley","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2012.11.014_bib0810","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0815","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00702-005-0327-z","article-title":"The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis","volume":"113","author":"Bartosik-Psujek","year":"2006","journal-title":"J Neural Trans"},{"key":"10.1016\/j.bcp.2012.11.014_bib0820","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"197","author":"Hesse","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2012.11.014_bib0825","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.exger.2009.10.010","article-title":"Total and phosphorylated tau protein as biological markers of Alzheimer's disease","volume":"45","author":"Hampel","year":"2010","journal-title":"Exp Gerentol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0830","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0304-3940(97)00215-2","article-title":"Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt\u2013Jakob disease","volume":"225","author":"Otto","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2012.11.014_bib0835","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0197-4580(01)00309-8","article-title":"Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group","volume":"23","author":"Shoji","year":"2002","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0840","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ana.1054","article-title":"Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease","volume":"50","author":"Itoh","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0845","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0850","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/JMN:23:1-2:115","article-title":"Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease Original data and review of the literature","volume":"23","author":"Lewczuk","year":"2004","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0855","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.bcp.2012.11.014_bib0860","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib0865","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative studies","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0870","doi-asserted-by":"crossref","first-page":"s85","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattson","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bcp.2012.11.014_bib0875","doi-asserted-by":"crossref","unstructured":"Breno SO, Diniz, Jony A, Pinto Jr, Orestes Vicente Forlenz. Do CSF total tau, phosphorylated tau, and \u03b2-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008;9:172\u201382.","DOI":"10.1080\/15622970701535502"},{"key":"10.1016\/j.bcp.2012.11.014_bib0880","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneurol.2010.179","article-title":"Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people","volume":"67","author":"De Meyer","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0885","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0890","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10048-008-0150-4","article-title":"Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta","volume":"10","author":"Kauwe","year":"2009","journal-title":"Neurogenetics"},{"key":"10.1016\/j.bcp.2012.11.014_bib0895","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neurobiolaging.2012.03.006","article-title":"Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease","volume":"34","author":"Grill","year":"2013","journal-title":"Neuroimag Initiat Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0900","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","article-title":"A\u03b2 Immunotherapy: Intracerebral Sequestration of A\u03b2 by an Anti-A\u03b2 Monoclonal Antibody 266 with High Affinity to Soluble A\u03b2","volume":"29","author":"Yamada","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0905","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2007.05.002","article-title":"Clinical attrition due to biased preclinical assessments of potential efficacy","volume":"115","author":"Lindner","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib0910","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archgenpsychiatry.2011.28","article-title":"Excess significance bias in the literature on brain volume abnormalities","volume":"68","author":"Ioannidis","year":"2011","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.bcp.2012.11.014_bib0915","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/483531a","article-title":"Raise standards for preclinical cancer research","volume":"483","author":"Begley","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.11.014_bib0920","unstructured":"National Alzheimer's Project Act 2011. http:\/\/aspe.hhs.gov\/daltcp\/napa\/NatlPlan.shtml."},{"key":"10.1016\/j.bcp.2012.11.014_bib0925","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bcp.2012.08.005","article-title":"Nous sommes toutes des bacteries: implications for medicine, pharmacology and public health","volume":"84","author":"Triggle","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0930","unstructured":"Kolata G. Years later, no magic bullet against Alzheimer's disease. New York Times; 2010, August 28, 2010. http:\/\/www.nytimes.com\/2010\/08\/29\/health\/research\/29prevent.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib0935","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nsmb.1591","article-title":"Converging concepts of protein folding in vitro and in vivo","volume":"16","author":"Hartl","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0940","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.biocel.2012.04.023","article-title":"Endoplasmic reticulum: the unfolded protein response is tangled in neurodegeneration","volume":"44","author":"Hoozemans","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0945","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1126\/science.1222951","article-title":"A unifying role for prions in neurodegenerative diseases","volume":"336","author":"Pruisner","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib0950","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.neurobiolaging.2012.01.096","article-title":"Tauopathies: a single therapy for all?","volume":"3","author":"Spillantini","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib0955","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"42","author":"Lee","year":"2001","journal-title":"Ann Rev Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0960","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12035-012-8271-z","article-title":"Mitochondrial dysfunction\u2014a pharmacological target in Alzheimer's disease","volume":"46","author":"Eckert","year":"2012","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bcp.2012.11.014_bib0965","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease","volume":"103","author":"Mahey","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2012.11.014_bib0970","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1074\/jbc.M110.151084","article-title":"Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2012.11.014_bib0975","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","article-title":"Amyloid-beta\/Fyn-induced synaptic network and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease","volume":"31","author":"Roberson","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib0980","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrd2111","article-title":"Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases","volume":"6","author":"Mazanetz","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib0985","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1042\/BJ20101485","article-title":"AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid \u03b2-peptide exposure","volume":"434","author":"Thornton","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2012.11.014_bib0990","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2164-11-25","article-title":"High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation","volume":"11","author":"Azorsa","year":"2010","journal-title":"BMC Genom"},{"key":"10.1016\/j.bcp.2012.11.014_bib0995","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3233\/JAD-2010-1271","article-title":"Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase","volume":"19","author":"Tremblay","year":"2010","journal-title":"Arg J Alzheimers Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib1000","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2012.07.001","article-title":"Tau as a therapeutic target in neurodegenerative disease","volume":"136","author":"Himmelstein","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib1005","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.11.014_bib1010","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI36245","article-title":"Deletion of GSK-3\u03b2 in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation","volume":"118","author":"Kerkela","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2012.11.014_bib1015","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1016\/j.febslet.2006.06.021","article-title":"Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine","volume":"589","author":"Chohan","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2012.11.014_bib1020","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2012.11.014_bib1025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neuropharm.2010.01.016","article-title":"Tau protein and tau aggregation inhibitors","volume":"59","author":"Bulic","year":"2010","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1030","unstructured":"Alzheimer Research, Forum, Chicago: Out of the Blue-, A., Tau-based Treatment for AD? August 7, 2008. http:\/\/www.alzforum.org\/new\/detail.asp?id=1892."},{"key":"10.1016\/j.bcp.2012.11.014_bib1035","unstructured":"Kitamura M. TauRx begins late-stage trials on Alzheimer's drug. Bloomberg October 30, 2012. http:\/\/www.bloomberg.com\/news\/2012-10-30\/taurx-begins-late-stage-trials-on-alzheimer-s-drug.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib1040","unstructured":"Whalen J. An outcast among peers gains traction on Alzheimer's Cure. Wall Street J, November 10, 2012. http:\/\/online.wsj.com\/article\/SB10000872396390443624204578060941988428604.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib1045","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1523\/JNEUROSCI.4922-11.2012","article-title":"The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive defects and Alzheimer's-like pathology in an interventional study with aged tau transgenic mice","volume":"32","author":"Zhang","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib1050","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","article-title":"Taupathy-like abnormalities and neurologic defects in mice immunized with neuronal tau protein","volume":"63","author":"Rosenmann","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1055","doi-asserted-by":"crossref","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","article-title":"Immunotherapy targeting pathophysiological tau prevents cognitive decline in a new tangle mouse model","volume":"30","author":"Boutajangout","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib1060","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2012.11.014_bib1065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbadis.2009.10.006","article-title":"Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology","volume":"1802","author":"Moreira","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2012.11.014_bib1070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2012.11.014_bib1075","unstructured":"Alzheimer Research Forum. Dimebon disappoints in Phase 3 trial. March 4, 2010. http:\/\/www.alzforum.org\/new\/detail.asp?id=2387."},{"key":"10.1016\/j.bcp.2012.11.014_bib1080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/ern.09.18","article-title":"Metabolic links between diabetes and Alzheimer's disease","volume":"9","author":"Maher","year":"2009","journal-title":"Exp Rev Neurother"},{"key":"10.1016\/j.bcp.2012.11.014_bib1085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.arr.2011.01.001","article-title":"Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?","volume":"10","author":"Correia","year":"2011","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.bcp.2012.11.014_bib1090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2005.01.004","article-title":"Insulin, insulin-degrading enzyme and amyloid-\u03b2 peptide in Alzheimer's disease: review and hypothesis","volume":"27","author":"Qui","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2012.11.014_bib1095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/NEN.0b013e3181afe475","article-title":"Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity","volume":"68","author":"Miners","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JAD-2006-10113","article-title":"Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease","volume":"10","author":"de la Monte","year":"2006","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib1105","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1073\/pnas.1000645107","article-title":"Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A\u03b2 deposition in an Alzheimer mouse model with diabetes","volume":"107","author":"Takeda","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2012.11.014_bib1110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-\u03b2 peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease","volume":"19","author":"Li","year":"2010","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib1115","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2012.11.014_bib1120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/mp.2010.17","article-title":"Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress","volume":"5","author":"Manolopoulos","year":"2010","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.bcp.2012.11.014_bib1125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3233\/JAD-2010-100795","article-title":"Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease","volume":"22","author":"Gil-Bea","year":"2010","journal-title":"J Alzheim Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib1130","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/jc.2010-2961","article-title":"Insulin suppresses the expression of amyloid precursor protein presenilins, and glycogen synthase kinase-3\u03b2 in peripheral blood mononuclear cells","volume":"96","author":"Dandona","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2012.11.014_bib1135","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-resistance IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2012.11.014_bib1140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tibs.2008.01.004","article-title":"A new take on prions: preventing Alzheimer's disease","volume":"33","author":"Hooper","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bcp.2012.11.014_bib1150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02778005","article-title":"Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy","volume":"8","author":"Baker","year":"1994","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1155","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMcibr1202401","article-title":"The spread of neurodegenerative disease","volume":"366","author":"Hardy","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuint.2010.12.003","article-title":"Alzheimer's disease plaques and tangles: cemeteries of a pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction","volume":"58","author":"Carter","year":"2011","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bcp.2012.11.014_bib1165","doi-asserted-by":"crossref","first-page":"e29480","DOI":"10.1371\/journal.pone.0029480","article-title":"Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels","volume":"6","author":"Feart","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2012.11.014_bib1170","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1073\/pnas.1110789109","article-title":"A\u03b2 neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors","volume":"109","author":"You","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2012.11.014_bib1175","doi-asserted-by":"crossref","first-page":"e33552","DOI":"10.1371\/journal.pone.0033552","article-title":"The zinc dyshomeostasis hypothesis of Alzheimer's disease","volume":"7","author":"Craddock","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2012.11.014_bib1180","doi-asserted-by":"crossref","first-page":"a006395","DOI":"10.1101\/cshperspect.a006395","article-title":"Symptomatic and nonamyloid\/tau based pharmacologic treatment for Alzheimer disease","volume":"2","author":"Aisen","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1185","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrd3869","article-title":"Drug repositioning for Alzheimer's disease","volume":"11","author":"Corbett","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib1190","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nbt0712-571a","article-title":"NCATS launches drug repurposing program","volume":"30","author":"Allison","year":"2012","journal-title":"Nat Biotech"},{"key":"10.1016\/j.bcp.2012.11.014_bib1195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1212\/WNL.47.2.425","article-title":"Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease. A review of 17 epidemiologic studies","volume":"47","author":"McGeer","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2012.11.014_bib1200","doi-asserted-by":"crossref","unstructured":"Jaturapatporn D, Isaac MGEKN, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Lib 2012. CD006378.","DOI":"10.1002\/14651858.CD006378.pub2"},{"key":"10.1016\/j.bcp.2012.11.014_bib1205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0301-0082(00)00025-3","article-title":"Neuroprotection by estradiol","volume":"63","author":"Garcia-Segura","year":"2001","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1210","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The women's health initiative memory study: a randomized controlled trial","volume":"289","author":"Shumaker","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bcp.2012.11.014_bib1215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1039\/C0NP00027B","article-title":"Natural products as a source of Alzheimer's drug leads","volume":"28","author":"Williams","year":"2011","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.bcp.2012.11.014_bib1220","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","article-title":"Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series","volume":"69","author":"Hajjar","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1225","doi-asserted-by":"crossref","first-page":"16743","DOI":"10.1073\/pnas.1208011109","article-title":"Epidermal growth factor receptor is a preferred target for treating Amyloid-\u03b2-induced memory loss","volume":"109","author":"Wang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2012.11.014_bib1230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-2094-5-2","article-title":"Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration","volume":"5","author":"Tobnick","year":"2008","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.bcp.2012.11.014_bib1235","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nrd2665","article-title":"Sirtuins\u2013novel therapeutic targets to treat age-associated diseases","volume":"7","author":"Lavu","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib1240","doi-asserted-by":"crossref","unstructured":"H\u00e9bert SS, Sergeant N, Bu\u00e9e L. MicroRNAs and the regulation of tau metabolism. Int J Alz Dis 2012; 2012, Article ID 406561.","DOI":"10.1155\/2012\/406561"},{"key":"10.1016\/j.bcp.2012.11.014_bib1245","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3233\/JAD-2012-121186","article-title":"Cognitive enhancers (Nootropics). Part 1: Drugs interacting with receptors","volume":"32","author":"Froestl","year":"2012","journal-title":"J Alz Dis"},{"key":"10.1016\/j.bcp.2012.11.014_bib1250","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.bcp.2012.11.014_bib1255","unstructured":"Fierce Biotech. EnVivo Pharmaceuticals Announces Statistically Significant Improvement in Cognition and Clinical Function in Phase 2b Clinical Trial in Alzheimer's Disease. Jul 18, 2012. http:\/\/www.fiercebiotech.com\/press-releases\/envivo-pharmaceuticals-announces-statistically-significant-improvement-cogn-0#ixzz27c7jok4R."},{"key":"10.1016\/j.bcp.2012.11.014_bib1260","unstructured":"Datamonitor. Lundbeck: Alzheimers success may herald a new drug class? May 29, 2012. http:\/\/www.datamonitor.com\/store\/News\/lundbeck_alzheimers_success_may_herald_a_new_drug_class?productid=82FC2984-C6FA-4ECB-885C-52258E02B252."},{"key":"10.1016\/j.bcp.2012.11.014_bib1265","unstructured":"Herper M. How a failed Alzheimer's drug illustrates the drug industry's gambling problem. Forbes, August 8, 2012. http:\/\/www.forbes.com\/sites\/matthewherper\/2012\/08\/08\/how-a-failed-alzheimers-drug-illustrates-the-drug-industrys-gambling-problem\/."},{"key":"10.1016\/j.bcp.2012.11.014_bib1270","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","article-title":"Alzheimer's disease","volume":"56","author":"Castellani","year":"2010","journal-title":"Dis Mon"},{"key":"10.1016\/j.bcp.2012.11.014_bib1275","unstructured":"Drug Baron. \u201cIdea Bubbles\u201d: The dangers of big theories in low-validity environments August 8, 2012. http:\/\/www.tcpinnovations.com\/drugbaron\/?p=271."},{"key":"10.1016\/j.bcp.2012.11.014_bib1280","doi-asserted-by":"crossref","first-page":"114ps48","DOI":"10.1126\/scitranslmed.3003529","article-title":"Mapping the road forward in Alzheimer's disease","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1285","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.ajpath.2012.03.004","article-title":"The great amyloid gamble","volume":"180","author":"Marchesi","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2012.11.014_bib1290","series-title":"Bad pharma","author":"Goldacre","year":"2012"},{"key":"10.1016\/j.bcp.2012.11.014_bib1295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrd1012","article-title":"Modern biomedical research: an internally self-consistent universe with little contact with medical reality?","volume":"2","author":"Horrabin","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.11.014_bib1300","unstructured":"Kaiser J. MD Anderson launches $3 Billion \u2018Moon Shot\u2019 to fight cancer science insider, September 21, 2012. http:\/\/news.sciencemag.org\/scienceinsider\/2012\/09\/md-anderson-launches-3-billion-m.html."},{"key":"10.1016\/j.bcp.2012.11.014_bib1305","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011585","article-title":"Alzheimer Disease in 2020","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.pharmthera.2010.08.007","article-title":"The roles of TNF in brain dysfunction and disease","volume":"128","author":"Clark","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2012.11.014_bib1315","first-page":"1004","volume":"64","author":"Clark","year":"2012","journal-title":"Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales Pharmacol Rev"},{"key":"10.1016\/j.bcp.2012.11.014_bib1320","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1755-5949.2011.00245.x","article-title":"Systemic and central immunity in Alzheimer's Disease: therapeutic implications","volume":"18","author":"Butchart","year":"2012","journal-title":"CNS Neurosci Therap"},{"key":"10.1016\/j.bcp.2012.11.014_bib1325","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","author":"Jonsson","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1330","article-title":"TREM2 variants in Alzheimer's disease","author":"Guerreiro","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1335","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.20041611","article-title":"Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2","volume":"201","author":"Takahashi","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2012.11.014_bib1340","article-title":"Variant TREM2 as risk factor for Alzheimer's disease","author":"Neumann","year":"2012","journal-title":"New Eng J Med"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212007551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212007551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T20:44:11Z","timestamp":1562359451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295212007551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":268,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0006295212007551"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2012.11.014","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}